Mediwound Ltd (MDWD)
MediWound Ltd. is a biopharmaceutical company focused on tissue repair and regeneration through bio-therapeutic and non-surgical solutions. The company develops, manufactures, and commercializes products for use in the United States, Europe, and other international markets. Its marketed product, NexoBrid, is used to remove eschar in patients with deep partial- and full-thickness thermal burns and is supplied to burn centers and hospital burn units. MediWound is also developing EscharEx, a bromelain-based enzymatic therapy for chronic and other hard-to-heal wounds, as well as MW005, a topical biological candidate being studied for non-melanoma skin cancers. Incorporated in 2000, the company is headquartered in Yavne, Israel, and its common stock trades on NASDAQ under the symbol MDWD.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-MDWD
|
$12.15
|
-12.9% Downside
|
Fair
|
$30.67
|
119.8% Upside
|
Bargain
|
Fair
|
0.0%
|
November 17, 2026
|
5.1x
|
15.2x
|
180.1 M
|
153.4 M
|
4.6%
|
68.7%
|
-7.3
|
141.4%
|
